HSK40118

Phase 1Small molecule

Haisco Pharmaceutical Group Co., Ltd.

HSK40118 is one of 3 small molecule programs targeting EGFR Mutation. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EGFR MutationRecruiting

EGFR MutationPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in EGFR Mutation

#DrugCompanyPhaseTrials

PLB1004

AAvistone Biotechnology Co., Ltd.

Phase 2

1 2

H002

RRedCloud Bio

Phase 2

1 3

HSK40118

Haisco Pharmaceutical Group Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

EGFR Mutation

NCT06050980

Clinical

Trials by Indication[1]

EGFR Mutation1 trial

Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation

Recruiting· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT06050980·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HSK40118. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HSK40118 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HSK40118. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Haisco Pharmaceutical Group Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Haisco Pharmaceutical Group Co., Ltd.

HSK40118

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

EGFR Mutation1 trial

References

Drug Info

Quick Facts

Related News